Adapter protein for site-specific conjugation of payloads for targeted drug delivery

被引:19
作者
Backer, MV
Gaynutdinov, TI
Patel, V
Jehning, BT
Myshkin, E
Backer, JM
机构
[1] SibTech Inc, Newington, CT 06111 USA
[2] Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Res, Cleveland, OH 44109 USA
关键词
D O I
10.1021/bc0499477
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
High-affinity interactions of two fragments of human RNase I (1-15-aa Hu-tag and 21-125-aa HuS adapter protein) can be used for assembly of targeting drug delivery complexes. In this approach, a targeting protein is expressed as a fusion protein with a 15-aa Hu-tag, while HuS is conjugated to a drug (or a drug carrier) creating a "payload" module, which is then bound noncovalently to the Hu-tag of the targeting protein. Although this approach eliminates chemical modifications of targeting proteins, the payload modules are still constructed by random cross-linking of drugs or drug carriers to an adapter protein that might lead to functional heterogeneity of the complexes. To avoid this problem, we engineered an adapter protein HuS(N88C) with an unpaired cysteine in position 88 that can be directly modified without interference with activity of assembled targeting complexes. HuS(N88C) binds Hu-tagged annexin V with K-D of 50 +/- 6 nM, which is comparable to that of wil.d-type HuS. To demonstrate the utility of HuS(N88C) for developing uniform payload modules, we constructed a HuS(N88C)-lipid conjugate and inserted it into preformed liposomes loaded with a fluorescent dye. Targeting proteins, Hu-tagged vascular endothelial growth factor or Hu-tagged annexin V, were docked to liposomes decorated with HuS, and the assembled complexes delivered liposomes selectively to target cells.
引用
收藏
页码:1021 / 1029
页数:9
相关论文
共 18 条
[1]   Humanized docking system for assembly of targeting drug delivery complexes [J].
Backer, MV ;
Gaynutdinov, TI ;
Gorshkova, II ;
Crouch, RJ ;
Hu, T ;
Aloise, R ;
Arab, M ;
Przekop, K ;
Backer, JA .
JOURNAL OF CONTROLLED RELEASE, 2003, 89 (03) :499-511
[2]   Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery [J].
Backer, MV ;
Gaynutdinov, TI ;
Aloise, R ;
Przekop, K ;
Backer, JM .
PROTEIN EXPRESSION AND PURIFICATION, 2002, 26 (03) :455-461
[3]   Molecular vehicles for targeted drug delivery [J].
Backer, MV ;
Aloise, R ;
Przekop, K ;
Stoletov, K ;
Backer, JM .
BIOCONJUGATE CHEMISTRY, 2002, 13 (03) :462-467
[4]   Functionally active VEGF fusion proteins [J].
Backer, MV ;
Backer, JM .
PROTEIN EXPRESSION AND PURIFICATION, 2001, 23 (01) :1-7
[5]  
Blankenberg FG, 2004, J NUCL MED, V45, P1373
[6]   Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs [J].
Dubowchik, GM ;
Walker, MA .
PHARMACOLOGY & THERAPEUTICS, 1999, 83 (02) :67-123
[7]   Design and assembly of anti-CD16 ScFv antibody with two different linker peptides [J].
Feng, J ;
Xie, ZG ;
Guo, N ;
Shen, BF .
JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 282 (1-2) :33-43
[8]   Interaction of human pancreatic ribonuclease with human ribonuclease inhibitor - Generation of inhibitor-resistant cytotoxic variants [J].
Gaur, D ;
Swaminathan, S ;
Batra, JK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (27) :24978-24984
[9]   Chimeric ribonuclease as a source of human adapter protein for targeted drug delivery [J].
Gaynutdinov, TI ;
Myshkin, E ;
Backer, JM ;
Backer, MV .
PROTEIN ENGINEERING, 2003, 16 (10) :771-775
[10]   PROTEIN ENGINEERING OF ANTIBODY-BINDING SITES - RECOVERY OF SPECIFIC ACTIVITY IN AN ANTI-DIGOXIN SINGLE-CHAIN FV ANALOG PRODUCED IN ESCHERICHIA-COLI [J].
HUSTON, JS ;
LEVINSON, D ;
MUDGETTHUNTER, M ;
TAI, MS ;
NOVOTNY, J ;
MARGOLIES, MN ;
RIDGE, RJ ;
BRUCCOLERI, RE ;
HABER, E ;
CREA, R ;
OPPERMANN, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (16) :5879-5883